Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33326840)

  • 1. Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.
    Casagrande N; Borghese C; Favero A; Vicenzetto C; Aldinucci D
    Cancer Lett; 2021 Mar; 500():182-193. PubMed ID: 33326840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
    Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
    Aldinucci D; Celegato M; Casagrande N
    Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
    Aldinucci D; Borghese C; Casagrande N
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
    Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
    Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
    Montanari F; Diefenbach CS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
    Bello E; Brich S; Craparotta I; Mannarino L; Ballabio S; Gatta R; Marchini S; Carrassa L; Matteo C; Sanfilippo R; Gronchi A; Casali PG; Pilotti S; D'Incalci M; Frapolli R
    Br J Cancer; 2019 Sep; 121(6):464-473. PubMed ID: 31409911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
    Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
    J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
    Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
    Sánchez-Espiridión B; Martín-Moreno AM; Montalbán C; Figueroa V; Vega F; Younes A; Medeiros LJ; Alvés FJ; Canales M; Estévez M; Menarguez J; Sabín P; Ruiz-Marcellán MC; Lopez A; Sánchez-Godoy P; Burgos F; Santonja C; López JL; Piris MA; Garcia JF
    Br J Haematol; 2013 Aug; 162(3):336-47. PubMed ID: 23725219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
    Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
    Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.
    Arlt A; von Bonin F; Rehberg T; Perez-Rubio P; Engelmann JC; Limm K; Reinke S; Dullin C; Sun X; Specht R; Maulhardt M; Linke F; Bunt G; Klapper W; Vockerodt M; Wilting J; Pukrop T; Dettmer K; Gronwald W; Oefner PJ; Spang R; Kube D
    Mol Oncol; 2020 Mar; 14(3):571-589. PubMed ID: 31825135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
    Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
    Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
    Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
    Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.
    Tiacci E; Döring C; Brune V; van Noesel CJ; Klapper W; Mechtersheimer G; Falini B; Küppers R; Hansmann ML
    Blood; 2012 Nov; 120(23):4609-20. PubMed ID: 22955914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
    Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
    Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.